Understanding the interaction between the tumor and the immune system is crucial for developing effective treatments for GBM, particularly for patients with an unmethylated MGMT promoter and high MGMT expression, who face limited treatment options and a poor prognosis. The gene discussed is MGMT; the disease is glioblastoma.